A Study in Metastatic Melanoma Using a Lymphodepleting Conditioning [cyclophosphamide, fludarabine administered with radiotherapy] followed by Infusion of Anti-MART-1 TCR-Gene Engineered Lymphocytes [tumour-infiltrating lymphocytes] and Subsequent Peptide Immunization [melanoma DNA vaccine].
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin; Cyclophosphamide; Fludarabine; Melanoma vaccine
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 15 Mar 2012 Biomarkers information updated
- 27 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 27 Aug 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.